Literature DB >> 10427995

Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF.

B Saha1, A Saini, R Germond, P J Perrin, D M Harlan, T A Davis.   

Abstract

Although enhanced monocytopoiesis is a hallmark of leishmaniasis, its significance in determining the course of the disease has not been addressed. While the number of granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cells increases in the draining lymph nodes in a resistant mouse strain (C57BL/6) during disease, in a susceptible strain (BALB/c) the number of interleukin-3 (IL-3)-secreting cells increases. Treatment of BALB/c mice with anti-IL-3 antibody significantly reduces the disease score. Bone marrow macrophages derived under stimulation with IL-3 (IL-3-Mphi) or GM-CSF (GM-Mphi) differ functionally. GM-Mphi are significantly more responsive to IFN-gamma-induced augmentation and more refractory to IL-4-mediated suppression of anti-leishmanial activity than IL-3-Mphi. LPS-induced IL-12 and TNF-alpha secretion by both the susceptible and resistant strain-derived macrophage subsets are down-regulated. Despite down-regulation of IL-12 secretion, GM-Mphi favor expansion of IFN-gamma-secreting cells and IL-3-Mphi favor IL-6-dependent expansion of the IL-4-secreting Th subset. Adoptive transfer of leishmanial antigen-pulsed IL-3-Mphi and GM-Mphi prior to infection either aggravated or reduced the disease score, respectively, in BALB/c mice. Anti-IL-6 treatment reverted the Th subset profile not only in vitro but also in vivo, resulting in a reduced disease score in both infected BALB/c mice and IL-3-Mphi recipients. The disease score in IL-3-Mphi recipients is also reduced significantly after anti-IL-4 treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427995     DOI: 10.1002/(SICI)1521-4141(199907)29:07<2319::AID-IMMU2319>3.0.CO;2-3

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

Review 1.  Concepts of immunostimulation to increase antiparasitic drug action.

Authors:  K Noel Masihi
Journal:  Parasitol Res       Date:  2003-01-08       Impact factor: 2.289

2.  Mannan-binding lectin enhances susceptibility to visceral leishmaniasis.

Authors:  I K Santos; C H Costa; H Krieger; M F Feitosa; D Zurakowski; B Fardin; R B Gomes; D L Weiner; D A Harn; R A Ezekowitz; J E Epstein
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania.

Authors:  Nicholas J Lapara; Ben L Kelly
Journal:  J Inflamm (Lond)       Date:  2010-02-02       Impact factor: 4.981

4.  A novel subset of helper T cells promotes immune responses by secreting GM-CSF.

Authors:  J Zhang; A I Roberts; C Liu; G Ren; G Xu; L Zhang; S Devadas; Yufang Shi
Journal:  Cell Death Differ       Date:  2013-09-27       Impact factor: 15.828

5.  Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine.

Authors:  I S Leal; M Flórido; P Andersen; R Appelberg
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 6.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

7.  Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.

Authors:  R G Titus; G K DeKrey; R V Morris; M B Soares
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

8.  Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis.

Authors:  B Saha; A M D J Tonkal; S Croft; S Roy
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Authors:  Henry W Murray
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.